Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of artemisinin compound to promotion of treatment of chimeric antigen receptor T cells and pharmaceutical composition

A chimeric antigen receptor and artemisinin technology, applied in the field of biomedicine, can solve the problems of large side effects, neurotoxicity, and insufficient killing effect of target cells

Active Publication Date: 2020-10-20
SHENZHEN BINDEBIOTECH CO LTD
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although CAR-T cell therapy has achieved good results in some clinical trials, it will produce large side effects (such as cytokine release syndrome, neurotoxicity and off-target effects, etc.) The killing effect is not strong enough

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of artemisinin compound to promotion of treatment of chimeric antigen receptor T cells and pharmaceutical composition
  • Application of artemisinin compound to promotion of treatment of chimeric antigen receptor T cells and pharmaceutical composition
  • Application of artemisinin compound to promotion of treatment of chimeric antigen receptor T cells and pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] 1. Resuscitate the CD19-targeting CAR-T cells cryopreserved in liquid nitrogen, and culture the CAR-T cells overnight in complete medium without interleukin IL. Raji cells were cultured overnight in DMEM medium containing 10% FBS and 1% double antibody.

[0035] 2. Collect the overnight cultured CAR-T cells and target cells Raji cells, wash them once with PBS, centrifuge (300g, 4min), and discard the supernatant.

[0036] 3. Resuspend CAR-T cells and Raji cells with KBM 581 basal medium containing no interleukin IL and containing 1% fetal bovine serum, and adjust their cell density. Adjust the cell density of CAR-T to 2×10 6 cells / mL, 1×10 6cells / mL and 5×10 5 cells / mL, the cell density of the target cell Raji is 2×10 5 cells / mL.

[0037] 4. Take a U-shaped 96-well plate, and place 50 μL of CAR-T cells of different densities, 50 μL of Raji cells, and 0.5 μL of DMSO or different concentrations of dihydroartemisinin dissolved in DMSO in each well (the final concentra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of an artemisinin compound to preparation of a preparation for promoting treatment of malignant tumors, autoimmune diseases or AIDS by chimeric antigen receptor Tcells, and also provides a pharmaceutical composition for treating malignant tumors, autoimmune diseases or AIDS. The pharmaceutical composition comprises chimeric antigen receptor T cells and the artemisinin compound. By combining the chimeric antigen receptor T cells and the artemisinin compound, the dosage of the chimeric antigen receptor T cells can be reduced to reduce the side effects caused by the chimeric antigen receptor T cells on the premise of guaranteeing a good curative effect on diseases such as malignant tumors and the like, and meanwhile, the immunotherapy effect can be enhanced, so that the immunotherapy cost of the chimeric antigen receptor T cells is further reduced.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the new application of artemisinin compounds, in particular to the application and pharmaceutical composition of artemisinin compounds in promoting chimeric antigen receptor T cell therapy. Background technique [0002] Malignant diseases such as cancer are diseases that seriously endanger human health worldwide. Currently, the treatment methods for cancer include non-specific immunotherapy, active immunotherapy, adoptive cellular immunotherapy and so on. Among them, adoptive cellular immunotherapy is considered to be a method that may completely eliminate cancer cells in existing technologies. The chimeric antigen receptor T cell (CAR-T) technology is one of the latest immune cell technologies in the current adoptive cell reinfusion therapy technology. Receptors) are reinfused into the human body to activate T lymphocytes in a manner independent of the major histocompatibi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/17A61K31/357A61K31/366A61P31/18A61P35/00A61P35/02A61P37/02
CPCA61K31/357A61K31/366A61P31/18A61P35/00A61P35/02A61P37/02A61K2239/48A61K39/464412A61K39/4631A61K39/4611A61K2300/00C07K19/00
Inventor 刘茂玄许晨光唐超温丽联
Owner SHENZHEN BINDEBIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com